Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
AOX1 CRISPR Activation Plasmid (h): sc-403997-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- AOX1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- AOX1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by AOX1 CRISPR Activation Plasmid (h) and AOX1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the AOX1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: AOX1 Antibody (D-8): sc-365291
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AOX1 CRISPR Activation Plasmid (h) | sc-403997-ACT | 20 µg | $397.00 |
Human AOX1 encodes aldehyde oxidase 1, a molybdenum-dependent cytosolic enzyme that catalyzes oxidation of diverse aldehydes and N-heterocyclic compounds during phase I xenobiotic metabolism. AOX1 participates in redox homeostasis and interfaces with broader metabolic networks by generating reactive oxygen species as byproducts and contributing to clearance of endogenous aldehydes produced during lipid peroxidation. Variation in AOX1 expression or activity can alter cellular sensitivity to oxidative stress and influence metabolic phenotypes, making it relevant to studies of hepatic function and detoxification capacity. Dysregulated aldehyde handling has been linked to inflammatory and fibrotic processes, supporting investigation of AOX1 as a modifier in models of metabolic and oxidative injury.
AOX1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous AOX1 expression without altering the underlying DNA sequence.
AOX1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the AOX1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the AOX1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous AOX1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native AOX1 locus and enabling the study of AOX1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of AOX1 pathway restoration in tumor cells with silenced or reduced AOX1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.